On May 5, 2020, Athersys announced the first patients have been enrolled in Athersysﾒ pivotal Phase 2/3 study entitled, MultiStemﾮ Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA). The patients were enrolled at University Hospitalﾒs Cleveland Medical Center. Medpace, a leading contract research organization (CRO) based in Cincinnati, Ohio, is serving as the CRO for this study.